Group 1 - Heng Rui Pharmaceutical (01276) has successfully completed a public offering with a subscription rate of 455 times, raising approximately HKD 9.7473 billion from the global sale of about 224.5 million shares, with a share price set at HKD 44.050 [1] - The Hong Kong public offering accounted for 21.50% of the total shares, while international offerings made up 78.50% [1] - The stock opened high in the dark market and closed up 32.24% at HKD 58.25, with a trading volume of HKD 751 million [1] Group 2 - The Nasdaq China Golden Dragon Index fell by 1.18%, with major Chinese stocks mostly declining, including Xpeng Motors down over 7% [2] - The Dow Jones Industrial Average and S&P 500 showed minimal changes, while the Nasdaq Composite Index increased by 0.28% [2] Group 3 - OPEC+ is discussing a significant production increase for July, potentially maintaining a daily increase of 411,000 barrels for the third consecutive month, pending a decision in a ministerial meeting on June 1 [3] Group 4 - The U.S. House of Representatives passed the HR1 bill, which prohibits states from regulating AI for the next ten years [4] Group 5 - Xiaomi's CEO Lei Jun announced that the company plans to invest approximately RMB 200 billion in research and development over the next five years, highlighting its growth in various sectors including smartphones and electric vehicles [5] Group 6 - Yueda Group and the Swiss National Tourism Board announced a summer collaboration plan for 2025, featuring the character Ye Xiu from the IP "Full-Time Master" as a tourism ambassador [6] Group 7 - Xinhua Pharmaceutical (00719) received a drug registration certificate for ibuprofen suspension drops, which are used for treating fever in children [8] - The sales of ibuprofen in Chinese public medical institutions were approximately RMB 5.09 billion in 2023, enhancing Xinhua's competitive edge in the market [8] Group 8 - Shanghai Industrial Holdings (00363) plans to sell 475 million shares of Yuefeng at a premium of about 0.4%, with a total consideration of HKD 2.329 billion [9] Group 9 - Yiming Oncology (01541) is set to initiate a Phase III trial for IMM2510/AXN-2510 in China for first-line NSCLC treatment by mid-2026 [10] Group 10 - LIZHU Pharmaceutical (01513) intends to acquire 64.81% of a Vietnamese pharmaceutical company for approximately RMB 1.587 billion [11] Group 11 - Galen Pharmaceuticals (01672) received FDA approval for its oral IL-17 inhibitor ASC50 for treating moderate to severe plaque psoriasis [12] Group 12 - Gako Pharmaceuticals (01167) announced the approval of its KRAS G12C inhibitor for non-small cell lung cancer, triggering a milestone payment of RMB 50 million from a partner [13] Group 13 - Xinhua Insurance (01336) committed RMB 10 billion to subscribe to a private equity fund with a total size of RMB 20 billion [14] Group 14 - BOSS Zhipin (02076) reported a net profit of RMB 518 million for Q1 2025, a year-on-year increase of 111.53% [15][16] Group 15 - GAC Group (02238) plans to achieve mass production of self-developed components for intelligent robots by 2025, with a focus on various applications including security and logistics [17]